ファイザーは前払いで12.5億ドルを支払い、開発マイルストーンが達成された場合には48億ドルを支払う。この契約により、ファイザーは中国を除く世界規模でのがん治療薬の開発、製造、商業化の権利を取得する。ファイザーはまた、中国での商業化権利を取得するオプ ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Investing.com — ファイザー（NYSE:PFE）は、年間売上高624.6億ドル、時価総額1,307.6億ドルの製薬大手であるが、中国のバイオ医薬品企業3SBio Inc.（01530.HK）との間で、新規がん治療薬SSGJ-707の中国以外での開発および商業化に関する独占的ライセンス契約を締結した。

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

発表資料によると、今回の契約により、ファイザーは、 三生製薬（スリー・エス・バイオ）が現在、複数の腫瘍タイプを対象に臨床試験を実施し ...

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

The deal grants Pfizer rights to develop and commercialise a drug from Shenyang-based 3SBio currently in clinical testing for multiple tumor types, according to a press release. In addition to the ...